Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-02-18 @ 2:46 AM
Study NCT ID:
NCT02474251
Status:
COMPLETED
Last Update Posted:
2020-07-24
First Post:
2015-06-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brain Sleep Clearance of Amyloid-Beta Peptides
Sponsor:
NYU Langone Health
Organization:
Study Overview
Official Title:
Brain Sleep Clearance of Amyloid-Beta Peptides
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Brain SCRAPs
Brief Summary:
The 'Amyloid Cascade Hypothesis' posits that the accumulation of a peptide, amyloid beta (Aβ), in the brain is the initiating event in Alzheimer's disease (AD), however, the mechanisms involved are not well understood. Recent studies support the hypothesis that Aβ dynamics in the brain are influenced by the sleep-wake cycle, with increases in the production of soluble Aβ during wakefulness and decreases during non-rapid eye movement (NREM) sleep, and more specifically on NREM stage 3 (also called slow wave sleep \[SWS\]). These changes produce a consistent diurnal pattern in the cerebrospinal fluid (CSF) that has been documented in murine models and in humans. By better understanding this sleep-wake relationship the investigators hope to identify how sleep disorders accelerate the progression of AD in the elderly (which has been demonstrated by multiple epidemiological studies) and, in turn, identify novel therapeutic targets for AD prevention.
The purpose of this study is to elucidate how soluble amyloid beta (Aβ) levels in the brain are influenced by the sleep-wake cycle in humans, and to test the directionality of this relationship through sleep disruption experiments. The investigators will test two models. The first model will test how, prior to amyloid deposition, brain soluble Aβ levels may be relatively increased in the elderly by two mechanisms: a) loss of total sleep time and SWS that occur with normal aging; and b) sleep disturbances such as Sleep Disordered Breathing (SDB) or insomnia that are common in late life (Aim 1). The second model will test how stage-specific sleep disruption may lead to increased CSF Aβ42 levels (Aim 2). A group of adults with diagnosed severe SDB and good continuous positive airway pressure (CPAP) compliance will be used to test this model sleep deprivation experiments using therapeutic CPAP vs. sham CPAP.
This project will be the first to explore the protective effect of SWS on Aβ42 dynamics in a group of cognitively normal elderly subjects as well as the effect of acute sleep disruption by CPAP withdrawal on CSF Aβ42 levels in a well characterized clinical sample of severe obstructive SDB patients on treatment with CPAP. The results from this study will improve our understanding of the nature of the Aβ diurnal pattern and the brain consequences of full night sleep disruptions as well as sleep disruptions during specific stages of sleep.
The purpose of this study is to elucidate how soluble amyloid beta (Aβ) levels in the brain are influenced by the sleep-wake cycle in humans, and to test the directionality of this relationship through sleep disruption experiments. The investigators will test two models. The first model will test how, prior to amyloid deposition, brain soluble Aβ levels may be relatively increased in the elderly by two mechanisms: a) loss of total sleep time and SWS that occur with normal aging; and b) sleep disturbances such as Sleep Disordered Breathing (SDB) or insomnia that are common in late life (Aim 1). The second model will test how stage-specific sleep disruption may lead to increased CSF Aβ42 levels (Aim 2). A group of adults with diagnosed severe SDB and good continuous positive airway pressure (CPAP) compliance will be used to test this model sleep deprivation experiments using therapeutic CPAP vs. sham CPAP.
This project will be the first to explore the protective effect of SWS on Aβ42 dynamics in a group of cognitively normal elderly subjects as well as the effect of acute sleep disruption by CPAP withdrawal on CSF Aβ42 levels in a well characterized clinical sample of severe obstructive SDB patients on treatment with CPAP. The results from this study will improve our understanding of the nature of the Aβ diurnal pattern and the brain consequences of full night sleep disruptions as well as sleep disruptions during specific stages of sleep.
Detailed Description:
Evaluations and procedures performed by the participants in:
Aim 1 Subjects were newly enrolled normal elderly or normal elderly recruited from R01HL118624-01 and evaluated according to the studies protocol.
Visit 1: During this visit, participants will undergo a complete physical exam, neurological examination, psychiatric interview, sleep interview, neuropsychological testing, Heart testing (EKG), laboratory analysis of blood. (90cc)
Visit 2: During this visit, participants will undergo an MRI scan and be educated on completing home monitoring of sleep wake cycle with actigraphy.
Visit 3: Patients will receive one FBB PET/MR scan to establish amyloid status.
Visit 4: Patients will undergo one night of NPSG with maze task prior to the subjects' scheduled morning LP with collection of CSF (15 cc).
Aim 2 All subjects will receive a complete evaluation (outlined below). Visit 1 and visit 2 will be used to screen subjects for inclusion.
Visit 1: During this visit participant will undergo a complete physical exam, neurological examination, psychiatric interview, sleep interview, psychometric testing, heart testing (EKG), laboratory analysis of blood. (90cc)
Visit 2: During this visit patient will undergo an MRI scan and be educated on completing home monitoring of sleep wake cycle with actigraphy.
Visit 3: Patients will undergo one night of NPSG at MSSM with either consistent use of CPAP or use of Sham CPAP to model discontinuation. Approximately, 10 hours after sleep onset participant will have a LP with collection of CSF. They will also complete 3D Visual Maze task the night of in lab assessment and the morning after, right before the LP (15 cc).
Visit 4: Patients will undergo one night of NSPG at MSSM with either consistent use of CPAP or use of Sham CPAP to model discontinuation. Approximately, 10 hours after sleep onset participant will have a LP with collection of CSF. They will also complete 3D Visual Maze task the night of in lab assessment and the morning after, right before the LP (15 cc)
Incidental findings from study procedures (except for CSF analyses and ApoE genotyping) will be communicated to study subjects by the Study Physician.
Aim 1 Subjects were newly enrolled normal elderly or normal elderly recruited from R01HL118624-01 and evaluated according to the studies protocol.
Visit 1: During this visit, participants will undergo a complete physical exam, neurological examination, psychiatric interview, sleep interview, neuropsychological testing, Heart testing (EKG), laboratory analysis of blood. (90cc)
Visit 2: During this visit, participants will undergo an MRI scan and be educated on completing home monitoring of sleep wake cycle with actigraphy.
Visit 3: Patients will receive one FBB PET/MR scan to establish amyloid status.
Visit 4: Patients will undergo one night of NPSG with maze task prior to the subjects' scheduled morning LP with collection of CSF (15 cc).
Aim 2 All subjects will receive a complete evaluation (outlined below). Visit 1 and visit 2 will be used to screen subjects for inclusion.
Visit 1: During this visit participant will undergo a complete physical exam, neurological examination, psychiatric interview, sleep interview, psychometric testing, heart testing (EKG), laboratory analysis of blood. (90cc)
Visit 2: During this visit patient will undergo an MRI scan and be educated on completing home monitoring of sleep wake cycle with actigraphy.
Visit 3: Patients will undergo one night of NPSG at MSSM with either consistent use of CPAP or use of Sham CPAP to model discontinuation. Approximately, 10 hours after sleep onset participant will have a LP with collection of CSF. They will also complete 3D Visual Maze task the night of in lab assessment and the morning after, right before the LP (15 cc).
Visit 4: Patients will undergo one night of NSPG at MSSM with either consistent use of CPAP or use of Sham CPAP to model discontinuation. Approximately, 10 hours after sleep onset participant will have a LP with collection of CSF. They will also complete 3D Visual Maze task the night of in lab assessment and the morning after, right before the LP (15 cc)
Incidental findings from study procedures (except for CSF analyses and ApoE genotyping) will be communicated to study subjects by the Study Physician.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 5R21AG049348-02 | NIH | None | https://reporter.nih.gov/quic… | View |